SJIF Impact Factor (2026): 8.863| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 5 | May 2026 - Peer Reviewed Journal

FORMULATION DEVELOPMENT OPTIMIZATION AND EVALUATION OF TASTE MASKED DOSAGE FORMS

Ravindra Vishnu Kakad[1], Mr. Dr. Amol G. Jadhao[2]
Research Scholar[1], Research Guide[2]
Gawande College of Pharmacy, Sakharkherda, Maharshtra, India, 443202 [1,2]

ABSTRACT

Taste masking plays a crucial role in the development of oral pharmaceutical formulations, particularly in improving patient compliance among pediatric, geriatric, and sensitive patient populations. Many active pharmaceutical ingredients possess an inherently bitter or unpleasant taste, which can lead to poor adherence and reduced therapeutic efficacy. Therefore, effective taste masking strategies are essential to ensure patient acceptability without compromising drug release and bioavailability.

Oral drug delivery systems, although widely preferred due to their convenience and non-invasive nature, face several challenges, including the rapid interaction of drug molecules with taste receptors in the oral cavity, difficulty in masking highly water-soluble and intensely bitter drugs, and maintaining a balance between palatability and optimal drug release. Additionally, formulation stability, scalability, and regulatory compliance further complicate the development process.

Various taste masking techniques have been explored to overcome these challenges, ranging from conventional approaches such as the use of sweeteners, flavors, and viscosity modifiers to advanced methods including polymer coating, microencapsulation, ion-exchange resins, inclusion complexation, and lipid- or nanoparticle-based systems. The selection of an appropriate technique depends on the physicochemical properties of the drug and the desired dosage form.

Optimization of taste-masked formulations is typically achieved using systematic approaches such as Design of Experiments (DoE), enabling the identification of critical formulation variables and their impact on performance. Evaluation of taste masking efficiency involves both in vitro methods, such as dissolution studies in simulated saliva and electronic tongue analysis, and in vivo techniques, including human taste panel studies. Overall, advancements in formulation technologies continue to enhance the effectiveness of taste masking while ensuring desirable drug release characteristics and patient compliance.

KEYWORD: *Taste masking, Oral drug delivery, Patient compliance, Polymer coating, Ion-exchange resins, Nanotechnology ,Orally disintegrating tablets*

INTRODUCTION

Oral drug delivery systems remain the most widely preferred route of administration in pharmaceutical therapy due to their convenience, non-invasiveness, cost-effectiveness, and high patient acceptance. Tablets, capsules, suspensions, and orally disintegrating dosage forms are commonly used because they allow easy administration and flexibility in formulation design. Moreover, oral delivery facilitates self-medication, improves patient adherence, and reduces the need for medical supervision compared to parenteral routes.

Despite these advantages, one of the major challenges associated with oral formulations is the unpleasant or bitter taste of many active pharmaceutical ingredients (APIs). Drugs such as antibiotics, antihistamines, and certain analgesics often possess an inherently bitter taste, which becomes immediately perceptible when the dosage form disintegrates or dissolves in the oral cavity. This issue is particularly significant in fast dissolving tablets, oral films, and liquid formulations, where the drug comes in direct contact with taste buds, leading to poor palatability.

The impact of unpleasant taste is more pronounced in pediatric and geriatric populations. Children are highly sensitive to taste and may refuse medication if it is bitter, leading to incomplete dosing and therapeutic failure. Similarly, elderly patients, especially those with dysphagia or chronic illnesses, often require easy-to-administer dosage forms, but their acceptance is strongly influenced by taste. Poor palatability can result in reduced compliance, skipped doses, and ultimately diminished treatment outcomes.

To overcome these limitations, the development of effective taste masking technologies has become an essential aspect of modern pharmaceutical formulation. Taste masking not only improves the sensory characteristics of drugs but also enhances patient compliance and therapeutic efficacy. Various approaches, including the use of flavors and sweeteners, polymer coatings, complexation techniques, and advanced drug delivery systems, have been explored to minimize the interaction of drug molecules with taste receptors. Therefore, incorporating suitable taste masking strategies is critical for the successful development of patient-friendly oral dosage forms.

SJIF Impact Factor (2026): 8.863| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 5 | May 2026 - Peer Reviewed Journal

PHYSIOLOGY OF TASTE PERCEPTION

Structure of Taste Buds

Taste perception begins in specialized sensory organs known as taste buds, which are primarily located on the tongue within structures called papillae (fungiform, foliate, and circumvallate papillae). Each taste bud is a flask-shaped structure composed of approximately 50–100 specialized epithelial cells, including taste receptor cells, supporting cells, and basal cells. These cells are arranged around a central pore known as the taste pore, through which dissolved substances in saliva come into contact with receptor sites. Taste buds are also distributed in other regions of the oral cavity, such as the soft palate, pharynx, and epiglottis. The continuous regeneration of taste receptor cells ensures sustained sensitivity to taste stimuli.

Mechanism of Taste Perception

Taste perception is initiated when drug molecules or other chemical substances dissolve in saliva and diffuse through the taste pore to interact with taste receptor cells. This interaction triggers a series of biochemical and electrical events, leading to the generation of receptor potentials. Depending on the nature of the tastant, different transduction mechanisms are involved. For example, salty and sour tastes are mediated by ion channels, whereas sweet, umami, and bitter tastes are primarily detected through G-protein-coupled receptor (GPCR) pathways. Activation of these receptors leads to depolarization of taste cells and subsequent neurotransmitter release. The signal is then transmitted via afferent nerves (facial, glossopharyngeal, and vagus nerves) to the gustatory cortex in the brain, where it is interpreted as a specific taste sensation.

Bitter Taste Receptors and Drug Interaction

Bitter taste perception is particularly important in pharmaceutical sciences, as many drugs exhibit a strong bitter profile. Bitter taste is primarily mediated by a family of G-protein-coupled receptors known as T2R receptors, which are expressed on the surface of taste receptor cells. These receptors are highly sensitive and can detect a wide range of structurally diverse compounds, including many APIs. When a bitter drug binds to T2R receptors, it activates intracellular signaling pathways involving gustducin protein, leading to calcium ion release and neurotransmitter signaling, ultimately producing a bitter sensation.

The interaction between drugs and bitter taste receptors depends on factors such as drug solubility, concentration, molecular structure, and ionization state. Highly water-soluble drugs tend to dissolve rapidly in saliva, increasing their interaction with receptors and intensifying bitterness. Therefore, effective taste masking strategies aim to prevent or minimize this interaction by reducing drug solubility in the oral cavity, forming complexes, or creating physical barriers between the drug and taste receptors. Understanding the physiology of taste perception is thus essential for designing successful taste-masked pharmaceutical formulations.

Need for Taste Masking

Taste masking is a critical requirement in the development of oral pharmaceutical formulations, as the palatability of a drug directly influences patient acceptance and therapeutic success.

Patient Compliance Issues

Unpleasant or bitter taste is one of the major factors leading to poor patient compliance, particularly in oral dosage forms that dissolve or disintegrate in the mouth. Pediatric patients are highly sensitive to taste and may refuse medication if it is unpalatable, resulting in incomplete dosing and therapeutic failure. Similarly, geriatric patients, especially those suffering from dysphagia or chronic conditions, often rely on liquid or fast disintegrating dosage forms, where taste plays a significant role in acceptability. Poor taste can lead to dose skipping, incorrect administration, or discontinuation of therapy, ultimately reducing treatment efficacy. Therefore, improving palatability through effective taste masking is essential to enhance adherence and ensure optimal clinical outcomes.

Drugs Requiring Taste Masking

A wide range of drugs exhibit inherently bitter or unpleasant taste and require taste masking for successful formulation. Common examples include antibiotics (such as Amoxicillin and Ciprofloxacin), antihistamines (such as Cetirizine), analgesics (such as Ibuprofen), and certain antimalarial and antifungal drugs. These drugs are frequently formulated as syrups, suspensions, orally disintegrating tablets (ODTs), or oral films, where direct contact with taste buds is unavoidable. Highly water-soluble drugs pose an even greater challenge, as they dissolve rapidly in saliva, intensifying the perception of bitterness. Hence, taste masking becomes essential to improve patient acceptability without altering drug efficacy.

Regulatory Considerations

Regulatory agencies emphasize the importance of palatability, particularly for pediatric and geriatric formulations. Guidelines from organizations such as the U.S. Food and Drug Administration and the European Medicines Agency recommend the evaluation of taste and acceptability during drug development. For pediatric medicines, regulatory frameworks require the inclusion of palatability studies, such as human taste panels or validated in vitro techniques like electronic tongue analysis. Additionally, taste masking approaches must not compromise drug release, bioavailability, or safety. Excipients used for taste masking must also comply with

SJIF Impact Factor (2026): 8.863| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 5 | May 2026 - Peer Reviewed Journal

regulatory standards for safety and quality. Therefore, addressing taste-related issues is not only a formulation challenge but also a key regulatory requirement in the successful approval of oral pharmaceutical products.

Ideal Characteristics of Taste-Masked Dosage Forms

An ideal taste-masked dosage form should effectively conceal the unpleasant taste of the drug while maintaining its therapeutic performance and manufacturability. The following characteristics are essential for a successful formulation:

Absence of Bitter Taste in the Oral Cavity

The primary objective of taste masking is to prevent the drug from interacting with taste receptors in the oral cavity. An ideal formulation should ensure that no bitter or unpleasant taste is perceived during administration, even for highly water-soluble drugs. This can be achieved by creating a physical barrier (e.g., polymer coating), forming complexes (e.g., ion-exchange resins or inclusion complexes), or reducing drug solubility in saliva.

Rapid Drug Release in the Gastrointestinal Tract

While masking the taste in the mouth, the formulation must allow immediate or controlled release of the drug once it reaches the gastrointestinal (GI) tract. The taste masking technique should not hinder drug dissolution or absorption at the site of action. Ideally, the formulation should remain intact in the oral cavity but disintegrate or release the drug efficiently under gastric conditions (e.g., acidic pH).

Stability and Cost-Effectiveness

The dosage form should exhibit good physical, chemical, and microbial stability throughout its shelf life. Taste masking agents, polymers, or coatings used should not compromise the stability of the active pharmaceutical ingredient. Additionally, the formulation process should be cost-effective, utilizing readily available excipients and scalable techniques to ensure commercial viability.

Scalability and Manufacturability

An ideal taste-masked dosage form should be easy to manufacture using standard pharmaceutical equipment and processes such as direct compression, granulation, coating, or spray drying. The method should be reproducible, robust, and suitable for large-scale production. Minimal process complexity and ease of scale-up are crucial factors for successful industrial application.

Overall, a well-designed taste-masked formulation should strike a balance between palatability, drug release, stability, and manufacturability, ensuring both patient acceptability and therapeutic effectiveness.

Classification of Taste Masking Techniques

Taste masking techniques are broadly classified into **conventional** and **advanced approaches**, depending on the complexity of the method and the level of effectiveness required.

Conventional Methods

These are simple, cost-effective, and widely used techniques, mainly suitable for mildly bitter drugs.

• Use of Flavors and Sweeteners

- Addition of natural or artificial sweeteners (e.g., sucrose, aspartame) and flavors (fruit, mint, vanilla)
- Helps to **mask or overpower bitterness** rather than eliminate it
- Commonly used in syrups, suspensions, and chewable tablets
- Limitation: Ineffective for highly bitter drugs

• Use of Viscosity Enhancers

- Use of polymers like HPMC, xanthan gum, or sodium CMC
- Increases the **viscosity of formulation**, reducing drug diffusion to taste buds
- Provides a temporary masking effect
- Common in liquid formulations

• Use of Effervescent Systems

- Incorporation of effervescent agents (e.g., sodium bicarbonate + citric acid)
- Produces carbon dioxide, which **distracts taste perception**
- Enhances mouthfeel and reduces bitterness perception
- Used in effervescent tablets and granules

Advanced Techniques

These methods provide **effective and long-lasting taste masking**, especially for strongly bitter drugs.

SJIF Impact Factor (2026): 8.863| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 5 | May 2026 - Peer Reviewed Journal

a. Physical Methods

• Coating (Polymer Coating / Microencapsulation)

- Drug particles are coated with polymers (e.g., ethyl cellulose, Eudragit)
- Forms a **physical barrier** preventing drug release in the oral cavity
- Allows release in gastric pH
- Widely used in tablets, pellets, and granules

• Granulation

- Drug is embedded within granules using binders or polymers
- Reduces direct exposure of drug to taste receptors
- Suitable for tablets and sachets

• Adsorption (e.g., Silica, Resins)

- Drug is adsorbed onto carriers like silica or non-ion exchange resins
- Reduces drug solubility in saliva
- Improves handling and compressibility

b. Chemical Methods

• Prodrug Approach

- Chemical modification of drug into a **non-bitter derivative**
- Converted back to active form after administration
- Effective but involves complex synthesis

• Salt Formation

- Conversion of drug into a **less soluble or less bitter salt form**
- Alters taste and dissolution properties
- Limited applicability depending on drug chemistry

• Inclusion Complexes (e.g., Cyclodextrins)

- Drug is entrapped within the cavity of cyclodextrins such as Cyclodextrin
- Reduces interaction with taste receptors
- Improves solubility and stability

c. Ion Exchange Resin Method

• Drug–Resin Complex Formation

- Drug binds to ion exchange resins forming **drug-resinate complex**
- Complex is insoluble in saliva but releases drug in GI fluids

• Mechanism and Advantages

- In oral cavity: No dissociation → no taste perception
- In GI tract: Ion exchange with electrolytes → drug release
- Advantages:
  - Excellent taste masking
  - Controlled drug release possible
  - Stability enhancement

d. Novel Techniques

• Lipid-Based Systems

- Drug is incorporated into lipids or waxes
- Prevents dissolution in saliva
- Useful for sustained and taste-masked formulations

• Nanoparticles and Microspheres

- Drug encapsulated in nano/micro carriers
- Provides **effective barrier and controlled release**
- Enhances bioavailability

• Hot Melt Extrusion

- Drug dispersed in polymer matrix using heat
- Forms solid dispersion with masked taste
- Solvent-free and scalable process

• Spray Drying

- Drug and polymer solution converted into dry particles
- Forms microcapsules with taste masking properties

SJIF Impact Factor (2026): 8.863| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 5 | May 2026 - Peer Reviewed Journal

- Suitable for heat-sensitive drugs (with optimization)

Formulation Development Strategies

The development of taste-masked dosage forms requires a systematic and rational approach to ensure effective taste masking without compromising drug release, stability, and patient acceptability.

Selection of Drug Candidate

The first step in formulation development is the selection of a suitable drug candidate. Drugs that are highly bitter, water-soluble, and intended for oral administration are primary candidates for taste masking. Important factors to consider include:

- **Taste profile** (intensity and type of bitterness)
- **Solubility in saliva** (high solubility increases bitterness)
- **Dose and potency** (high-dose drugs are more difficult to mask)
- **pKa and ionization behavior**
- **Stability and compatibility with excipients**

Understanding these properties helps in choosing an appropriate taste masking strategy.

Selection of Taste Masking Technique

The choice of technique depends on the physicochemical characteristics of the drug and the intended dosage form. Key considerations include:

- **Extent of bitterness** (mild vs highly bitter drugs)
- **Drug solubility and permeability**
- **Required release profile (immediate or controlled release)**
- **Manufacturing feasibility and cost**

For example:

- Mild bitterness → flavors and sweeteners
- Highly bitter drugs → coating, ion-exchange resins, or microencapsulation
- Highly soluble drugs → complexation or polymer barrier techniques

A suitable technique should effectively mask taste while ensuring proper drug release in the gastrointestinal tract.

Excipients Selection (Polymers, Sweeteners, Flavors)

Excipients play a crucial role in enhancing palatability and stability of the formulation.

• Polymers

- Used for coating or matrix formation
- Examples: HPMC, ethyl cellulose, Eudragit
- Provide a barrier between drug and taste receptors

• Sweeteners

- Mask bitterness and improve mouthfeel
- Examples: sucrose, mannitol, aspartame, sucralose
- Selection depends on patient group (e.g., sugar-free for diabetics)

• Flavors

- Provide pleasant taste and aroma
- Examples: fruit flavors (orange, strawberry), mint, vanilla
- Should complement the drug's taste profile

Excipients must be safe, compatible, stable, and approved for pharmaceutical use.

Dosage Form Design

The choice of dosage form significantly influences taste masking efficiency and patient compliance.

• Tablets

- **Orally Disintegrating Tablets (ODTs):** Rapid disintegration in mouth; require effective taste masking
- **Chewable Tablets:** Taste is critical; use of sweeteners and flavors is essential
- Widely used due to stability and ease of manufacturing

• Suspensions

- Suitable for pediatric and geriatric patients
- Require viscosity enhancers and flavoring agents
- Taste masking achieved through coating, complexation, or sweetening

• Oral Films

- Thin, flexible films that dissolve rapidly in the oral cavity
- Require advanced taste masking techniques due to direct contact with taste buds

SJIF Impact Factor (2026): 8.863| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 5 | May 2026 - Peer Reviewed Journal

- Offer improved patient compliance and convenience

Summary

An effective formulation strategy integrates:

- Proper **drug selection**
- Appropriate **taste masking technique**
- Rational **excipient selection**
- Suitable **dosage form design**

This ensures optimal balance between **palatability, drug release, stability, and patient compliance**, leading to a successful pharmaceutical product.

Optimization of Taste-Masked Formulations

Optimization is a critical step in developing taste-masked dosage forms to achieve the best balance between **palatability, drug release, and stability**. Systematic optimization helps in identifying the ideal formulation variables and ensures reproducibility and robustness of the final product.

Design of Experiments (DoE)

Design of Experiments (DoE) is a statistical and systematic approach used to study the effect of multiple formulation variables simultaneously. It minimizes the number of experimental trials while maximizing the information obtained.

- Helps in identifying **critical formulation variables (independent variables)**
- Evaluates their impact on **responses (dependent variables)** such as taste masking and drug release
- Reduces time, cost, and experimental variability
- Provides mathematical models to predict formulation behavior

DoE is widely applied in pharmaceutical optimization to achieve a **Quality by Design (QbD)** approach.

Factorial Design and Response Surface Methodology

• Factorial Design

- Involves studying two or more factors at different levels (e.g., 2^2, 3^2 design)
- Evaluates **main effects and interaction effects** between variables
- Useful in preliminary screening of formulation parameters

• Response Surface Methodology (RSM)

- Advanced optimization technique used after factorial design
- Generates **3D response surface plots and contour plots**
- Helps in identifying the **optimal region** for formulation variables
- Provides a predictive model for optimization

Both methods are essential tools for developing robust and optimized taste-masked formulations.

Key Variables (Critical Formulation Parameters)

The following variables significantly influence the performance of taste-masked dosage forms:

• Polymer Concentration

- Higher polymer concentration enhances taste masking by forming a stronger barrier
- Excess polymer may delay drug release

• Coating Thickness

- Increased coating thickness improves taste masking efficiency
- Excessive thickness can reduce dissolution rate and bioavailability

• Drug-to-Polymer Ratio

- Determines the balance between taste masking and drug release
- Optimal ratio ensures adequate masking without compromising therapeutic effect

Optimization Criteria

The success of optimization is evaluated based on the following criteria:

• Taste Masking Efficiency

- Assessed using in vitro methods (simulated saliva, electronic tongue) or in vivo taste panels
- Should ensure minimal or no bitterness perception

• Drug Release Profile

- Immediate or controlled release as per formulation requirement
- Should comply with pharmacopeial standards
- Ensures therapeutic effectiveness

SJIF Impact Factor (2026): 8.863| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 5 | May 2026 - Peer Reviewed Journal

• **Stability**
- Physical, chemical, and microbial stability over time
- No degradation of drug or excipients
- Consistent performance during shelf life

Optimization integrates **statistical tools (DoE, factorial design, RSM)** with formulation science to:
- Identify critical variables
- Predict formulation behavior
- Achieve an optimal balance between **taste masking, drug release, and stability**

This approach ensures development of **robust, reproducible, and patient-friendly dosage forms**.

Evaluation of Taste-Masked Dosage Forms

Evaluation is essential to confirm that the developed formulation effectively masks the bitter taste while maintaining desired drug release, stability, and quality. It involves **preformulation, in-vitro, in-vivo, and other physicochemical assessments**.

Preformulation Studies

Preformulation studies provide essential information about the physicochemical properties of the drug and its compatibility with excipients.

• **Organoleptic Properties**
- Assessment of **color, odor, appearance, and taste**
- Helps in identifying the initial bitterness of the drug
- Provides baseline data for taste masking evaluation

• **Solubility**
- Determination of drug solubility in **water, saliva, and organic solvents**
- Highly soluble drugs require stronger taste masking techniques
- Influences formulation design and method selection

• **Drug–Excipient Compatibility**
- Evaluated using analytical techniques such as:
  - **FTIR (Fourier Transform Infrared Spectroscopy):** Detects functional group interactions
  - **DSC (Differential Scanning Calorimetry):** Identifies thermal behavior and compatibility
- Ensures no chemical interaction that may affect stability or efficacy

In-vitro Evaluation

In-vitro studies are conducted to assess taste masking efficiency and drug release behavior under controlled conditions.

• **Drug Release Studies**
- Performed using dissolution apparatus in suitable media
- Confirms that taste masking does not hinder drug release in GI conditions
- Provides release kinetics and profile

• **Taste Evaluation Using Simulated Saliva**
- Drug release tested in **simulated salivary fluid (pH ~6.8)**
- Measures the amount of drug released in the oral cavity
- Lower release indicates better taste masking

• **Electronic Tongue Analysis**
- Instrumental method that mimics human taste perception
- Uses sensor arrays to detect bitterness
- Provides **objective, reproducible, and quantitative** evaluation
- Reduces dependence on human volunteers

In-vivo Evaluation

In-vivo studies provide direct assessment of taste masking efficiency in humans.

• **Human Taste Panel Studies**
- Conducted using trained or volunteer subjects
- Participants evaluate bitterness, aftertaste, and overall acceptability
- Considered the **most reliable method** for taste evaluation

• **Hedonic Scale Evaluation**
- Uses a numerical scale (e.g., 1–5 or 1–9) to rate taste
- Example:
  - 1 = Extremely bitter
  - 5 = Acceptable / pleasant
- Helps in quantifying patient acceptability

SJIF Impact Factor (2026): 8.863| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 5 | May 2026 - Peer Reviewed Journal

Other Evaluation Parameters

Additional parameters ensure the quality and performance of the dosage form.

• Tablet Properties

- **Hardness:** Mechanical strength
- **Friability:** Resistance to breakage (<1% weight loss)
- **Disintegration time:** Important for ODTs and fast-release formulations

• Particle Size (for Nanoparticles/Microspheres)

- Determines drug release rate and taste masking efficiency
- Measured using techniques like DLS or microscopy

• Entrapment Efficiency

- Percentage of drug encapsulated within carrier system
- Higher entrapment → better taste masking
- Important for nanoparticle and microencapsulation systems

Evaluation of taste-masked dosage forms ensures:

- Effective **masking of bitterness**
- Desired **drug release profile**
- Adequate **stability and quality**

A combination of **preformulation, in-vitro, and in-vivo techniques** provides a comprehensive understanding of formulation performance.

Challenges in Taste Masking

Despite significant advancements in formulation technologies, effective taste masking remains a complex task due to multiple scientific and practical constraints.

Balancing Taste Masking with Drug Release

One of the primary challenges is achieving an optimal balance between **masking the unpleasant taste** and **maintaining appropriate drug release**. Techniques such as polymer coating, microencapsulation, or complexation may effectively prevent drug interaction with taste receptors in the oral cavity. However, excessive coating thickness or strong binding with carriers can delay or reduce drug release in the gastrointestinal tract, affecting bioavailability and therapeutic efficacy. Therefore, careful optimization is required to ensure that the drug remains masked in the mouth but is rapidly released under gastric conditions.

Stability Issues

Taste-masked formulations may face **physical and chemical stability challenges** during storage. Interactions between the drug and taste masking agents (e.g., polymers, resins, or complexing agents) can lead to:

- Drug degradation
- Changes in taste profile over time
- Altered drug release characteristics

Additionally, environmental factors such as temperature, humidity, and light may affect the integrity of coatings or complexes. Ensuring long-term stability without compromising taste masking efficiency is a major formulation challenge.

Scale-Up Difficulties

Techniques that are effective at the laboratory scale may not always be easily translated to industrial production. Processes such as microencapsulation, spray drying, and hot melt extrusion require:

- Specialized equipment
- Precise process control
- High production costs

Maintaining **uniform coating, consistent particle size, and reproducibility** during large-scale manufacturing can be difficult. Variations during scale-up may lead to batch-to-batch inconsistencies in taste masking and drug release.

Regulatory Concerns

Regulatory agencies require that taste-masked formulations meet stringent standards for **quality, safety, and efficacy**. Key concerns include:

- Demonstration of **palatability and patient acceptability**, especially for pediatric formulations
- Ensuring that taste masking does not affect **bioavailability**
- Use of **safe and approved excipients**
- Validation of evaluation methods (e.g., human taste panels or electronic tongue)

Regulatory approval may be challenging if adequate evidence is not provided to support both taste masking efficiency and therapeutic performance.

SJIF Impact Factor (2026): 8.863| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 5 | May 2026 - Peer Reviewed Journal

The major challenges in taste masking involve maintaining a delicate balance between **palatability, drug release, stability, scalability, and regulatory compliance**. Addressing these challenges requires a combination of **innovative formulation strategies, advanced optimization techniques, and thorough evaluation methods**.

Recent Advances and Innovations

Recent developments in pharmaceutical technology have significantly improved the effectiveness and precision of taste masking strategies. Advanced approaches such as nanotechnology, artificial intelligence, and 3D printing are transforming the design and development of patient-friendly dosage forms.

Nanotechnology-Based Taste Masking

Nanotechnology offers innovative solutions for masking the unpleasant taste of drugs by reducing particle size and encapsulating the drug within nanoscale carriers.

- **Nanoparticles, nanocapsules, and nanospheres** are used to entrap the drug, preventing direct interaction with taste receptors in the oral cavity
- Provides an effective **physical barrier**, minimizing drug release in saliva
- Enhances **bioavailability** due to increased surface area and improved dissolution in the gastrointestinal tract
- Can be combined with polymers or lipids for controlled release

This approach is particularly useful for highly bitter and poorly soluble drugs, offering dual benefits of **taste masking and enhanced drug delivery**.

Artificial Intelligence in Formulation Optimization

Artificial intelligence (AI) and machine learning are emerging as powerful tools in pharmaceutical formulation development.

- Enables **prediction of optimal formulation variables** based on experimental data
- Reduces the number of trials compared to traditional optimization methods like DoE
- Assists in identifying relationships between formulation parameters and responses (e.g., taste masking efficiency, drug release)
- Facilitates **Quality by Design (QbD)** and risk-based development

AI-driven models improve efficiency, reduce cost, and accelerate the development of robust taste-masked formulations.

3D Printing of Taste-Masked Dosage Forms

3D printing (additive manufacturing) is an emerging technology that allows precise control over drug formulation and dosage form design.

- Enables **layer-by-layer fabrication** of dosage forms with customized drug release profiles
- Allows incorporation of **taste-masked layers or compartments**, separating the drug from taste receptors
- Facilitates **personalized medicine**, especially for pediatric and geriatric patients
- Can combine multiple drugs with different release characteristics in a single dosage form

This technology offers flexibility in designing complex structures that enhance both **palatability and therapeutic performance**.
Recent innovations such as **nanotechnology, artificial intelligence, and 3D printing** are revolutionizing taste masking strategies by:

- Improving **efficiency and precision**
- Enabling **personalized and patient-centric formulations**
- Enhancing **bioavailability and drug performance**

These advancements are expected to play a crucial role in the future development of advanced oral drug delivery systems.

Applications

Taste masking technologies have wide-ranging applications across various patient groups and dosage forms, significantly enhancing acceptability and therapeutic outcomes.

Pediatric Formulations

Taste masking is most critical in pediatric drug delivery, as children are highly sensitive to bitter and unpleasant tastes. Formulations such as syrups, suspensions, orally disintegrating tablets (ODTs), and oral films require effective taste masking to ensure compliance. Technologies like flavoring, sweeteners, polymer coating, and ion-exchange resins are commonly used. Improved palatability leads to better adherence, accurate dosing, and successful therapy in pediatric patients.

Geriatric Formulations

In geriatric populations, taste masking is equally important due to age-related changes in taste perception and swallowing difficulties (dysphagia). Easy-to-administer dosage forms such as ODTs, dispersible tablets, and liquid formulations are preferred. Taste masking ensures patient comfort and encourages regular medication intake, particularly in chronic disease management where long-term therapy is required.

SJIF Impact Factor (2026): 8.863| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 5 | May 2026 - Peer Reviewed Journal

Fast Dissolving Dosage Forms

Fast dissolving dosage forms, including orally disintegrating tablets and oral films, disintegrate rapidly in the mouth and come into direct contact with taste buds. Therefore, effective taste masking is essential to prevent bitterness. Advanced techniques such as microencapsulation, coating, and complexation are widely used to maintain palatability while ensuring rapid drug release and onset of action.

Nutraceuticals

Taste masking is also widely applied in nutraceutical products, including vitamins, minerals, herbal extracts, and dietary supplements, which often possess unpleasant taste or odor. Incorporation of flavors, sweeteners, and encapsulation techniques improves consumer acceptance. This is particularly important for chewable tablets, gummies, and oral powders, where palatability directly influences consumer preference and market success.

Taste masking plays a vital role in enhancing the acceptability of pharmaceutical and nutraceutical products across diverse applications, ensuring improved **patient compliance, therapeutic effectiveness, and commercial viability**.

CONCLUSION

Taste masking is a vital component in the development of oral pharmaceutical formulations, as it directly influences patient compliance, acceptability, and overall therapeutic success. Unpleasant taste, particularly bitterness, remains a major barrier in effective drug administration, especially among pediatric and geriatric populations. Therefore, incorporating efficient taste masking strategies is essential to ensure accurate dosing and improved treatment outcomes.

A wide range of taste masking techniques have been explored, including conventional methods such as sweeteners and flavors, and advanced approaches like polymer coating, microencapsulation, ion-exchange resins, and inclusion complexation. While conventional methods are simple and cost-effective, they are often insufficient for highly bitter drugs. In contrast, advanced techniques provide more effective and reliable taste masking but may involve higher complexity and cost. The selection of an appropriate technique depends on drug properties, dosage form, and desired release characteristics, highlighting the importance of a rational and optimized formulation approach.

With the growing demand for patient-centric drug delivery, there is an increasing need for innovative and user-friendly formulations. Emerging technologies such as nanotechnology, artificial intelligence, and 3D printing offer promising solutions to overcome existing challenges and enhance formulation efficiency. Overall, the future of taste masking lies in the development of advanced, scalable, and patient-friendly dosage forms that ensure both palatability and therapeutic effectiveness.

REFERENCES

1. *www.foodiesite.com/articles/2000-11/cheese.jsp.*
2. *www.umds.ac.vk/physiology/jim taste olf.htm.*
3. *www.cf.ac.vk.biosi/staft/jacob/teaching/sensoy/taste.htm.*
4. *Gyton C. The chemical senses-Taste and smell. In Textbook of Medical Physiology. 7th ed. Hong Kong: W.B. Saunders Company; 1986. p. 745.*
5. *www.fda.com.*
6. *Hussain M.M., Barcelon S.A. Flavor enhancing and medicinal taste masking agent. U.S. Pat. No. 4,983,394 to Warner-Lambert Co.;1991.*
7. *Chase G.D, Gennaro AR., Gibson M.R. Pharmaceutical Necessities. In Remington's Pharmaceutial sciences. 16th ed. Pennsylvania: Mackpublishing company; 1980. p. 1229-31.*
8. *Lachman L, Lieberman H.A., kanig J.L. Liquids. In The Theory and Practice of Industrial Pharmacy. Pheladelphia: Lea and Febiger; 1987. p. 470,419.*
9. *Fuisz R.C. Taste masking of pharmaceutical floss with phenol. U.S. Pat. No. 5,028,632 to Fuisz pharmaceutical Ltd.;1991.*
10. *Lieberman H.A., Lachman L.(Eds.). Chewable Tablets. In Pharmaceutical Dosage Forms, Vol-1(Tablet). New York:Marcel Dekker Inc; 1981.. p. 387-391.*
11. *Delhi S., Patricia A.. Taste masking of phenolics using citrus flavors. U.S. Pat. No. 6,235,267 to Pfizer Inc.; 2001.*
12. *Depalmo G.A. Taste masked oral compositions containing ibuprofen. Eur. Pat. Appl. EP 05,60,207 to Aziende chemiche Riunite Angelini Francesco (ACRAF) S.P.A.;1993*
13. *Mody, Dhiraj S. Pediatric ibuprofen composition. U.S. Pat. No. 4,788,220 to American Home Products Corporation; 1998*
14. *Eby III,G.A. Taste masked zinc acetate compositions for oral absorption. U.S. Pat. No. 5,095,035; 1992*
15. *Augello, Michael. Croscarmellose taste masking. U.S. Pat. No. 6,099,865 to FMC corporation; 2000.*
16. *Bhardwaj, Sanjay. Palatable pharmaceutical compositions. U.S. Pat. No. 5,578,316 to Smithkline Beecham Corporation; 1996.*
17. *Pollinger, Norbert. Flavor masked pharmaceutical compositions U.S. Pat. No. 6,136,347 to Bayer Aktiengesellschaft; 2000.*
18. *Danny Y.U. Taste masked pharmaceutical liquid formulations. PCT Int. Appl. WO 01/03698 to Johnson and Johnson; 2001.*
19. *Iton, Akinori. Rapidly releasing and taste masking pharmaceutical dosage form. U.S. Pat. No. 6,221,402 to Pfizer Inc.; 2001.*
20. *Alkire, Todd G. Taste masking microparticles for oral dosage forms. U.S. Pat. No. 5,607,697 to Cima labs; 1997.*

SJIF Impact Factor (2026): 8.863| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 5 | May 2026 - Peer Reviewed Journal

21. *Hoy, Michel R. Taste Masked coating for preparation of chewable pharmaceutical tablets. U.S. Pat. No. 5,489,436 to Mcheil-PPC Inc; 1996.*
22. *Ventourar , Kimon. Swellable pellets. U.S. Pat. No. 4,882,169 to Zyma Sa; 1989.*
23. *Seager, Harry. Pharmaceutical formulations U.S. Pat. No. 4,016,254 to Beecham Group Limited; 1977.*
24. *Cumming, Kennels I.. Taste masked formulations. U.S. Pat. No. 6,153,220 to Elan corporation PLC; 2000.*
25. *Morella, Angelo M. Taste masked liquid suspensions. U.S. Pat. No. 6,197,348 to FH Faulding and co. Limited; 2001.*
26. *Yojima T., Nogata A. Particle design for taste masking using spray-congealing technique. Chem Pharm. Bull. 1996; 44: 187-191.*
27. *Ndesendo V. M. K., Meixner W. Microencapsulation of chloroquine diphosphate by Eudragit RS.100. J. Microencap. 1996; 13: 1-8*
28. *Mauger J.W., Robinson D.H. Coating technology for taste masking orally administered bitter drugs. U.S. Pat. No 5,728,403 to university of the braska ; 1998.*
29. *Wurster D.E. Particle coating method. In Pharmaceutical Dosage Form.New York: Marcel Dekker Inc; 1981. p. 119.*
30. *Habib Y.S., Shangraw R.. Cushioning beads and tablet comprising the same capable of forming a suspension. U.S. Pat. No. 5,780,055 to University at Maryland, Baltmore; 1998.*
31. *Mehta, Atul M.. Taste masked pharmaceutical composition. U.S. Pat. No. 4,800,087; 1989.*
32. *Friend D.R., Ng S. Taste masked microcapsule composition and methods of manufacture. U.S. Pat. No. 6,139,865 to Eurand America Inc.; 2000.*
33. *Dauglas, Stephen I. Taste masking compositions of Ranitidine U.S. Pat. No. 5,635,200 to Glaxo Group ltd; 1997*
34. *Deasy. Ion exchange resin in microencapsulation. Newyork: Marcel Dekker Inc; 1980. p. 150*
35. *Reynold, E.V. Ion exchange resin. In Martindale The Extra Pharmacopoeia. 28th Edition. London: Pharmaceutical Press; 1982. p. 869.*
36. *Swarbrick, J., Boylon, S.C. Ion exchange resin. In Encylopedia of Pharmaceutical Technology (Vol. 8). New York: Marcel Dekker Inc.; 1990. p. 203-216*
37. *Cristal, M. Particle Application of ion exchange resins. Manuf. Chem. 1985; 56: 50-53.*
38. *Bassett, Denney R.C., Jeffery G.H. Ion exchange. In Vogel's Textbook of Quantitative Inorganic Analysis. 4th edition. England: Longman scientific and Technical; 1978 . p. 165-172.*
39. *Eichman, M.L. Drug resin complexes stabilized by chelating agents. U.S. Pat. No. 5,980,882 to Medeva Pharm. Manuf. ; 1999.*
40. *Motyoka, S., Nairn, J.G. Influence of coating on release rate of anion from ion exchange resins beads. J.pharm. Sci. 1978; 67: 500-503.*
41. *Wen, B., Ramsay M.P.. Antitussive drugs delivered by ion exchange resins. U.S. Pat. No. 6,001,392 to Warner-Lambert Company; 1999.*
42. *Borodkin, S. Iron-resin adsorbate. U.S. Pat. No. 3,947,572 to Abbott Laboratories ; 1976.*
43. *Raghunathan, Y. Prolonged release pharmaceutical preparations. U.S. Pat. No. 4,221,778 to Pennewalt Corp.; 1980 .*
44. *Sheumaker, J.L. Liquid prolonged release pharmaceutical formulations containing ionic constituents. U.S. Pat. No. 4,762,709 to Pennewalt Corp; 1988.*
45. *Agarwal, R.; Mital, R. Studies of ion exchange resin complex of chloroquine phosphate. Drug Dev. Ind. Pharm. 2000; 26: 773- 776.*
46. *Lang, P.M.. Preparation and use of ion exchange resin loaded with quinolone carboxylic acid derivatives. U.S. Pat. No. 5,152,986 to Bayer Aktiengesellschaft ; 1992.*
47. *Louis, M., Cliflon, N.S. D-methorphan compositions and method of making same U.S. Pat. No. 3,346,449 to Roche Inc.; 1967. 13*
48. *Manek S.P., Kamath V.S. Evaluation of Indion CRP 244 and CRP 254 as sustained release and taste masking agents. Indian J. Pharm. Sci. 1981; 43: 209-212.*
49. *LY, MF, Borodkin S. Antibiotic polymer compositions. U.S. Pat. No. 4,808,411 to Abbott Laboratories; 1989.*
50. *LV, MF,Borodkin, S. A polymer carrier System for taste masking of macrolide antibiotics. Pharm. Res. 1991; 8: 706-712.*
51. *Gao, R.. Taste masking of oral quinolone liquid preparations using ion exchange resins. PCT Int. Appl. Wo 01/05431 to Schering-Plough Ltd.; 2001.*
52. *Leonard, G.S., Cooper, D. Oral liquid compositions containing paroxetine resinate. U.S. Pat. No. 5,811,436 to Smithkline Beecham Plc.; 1998.*
53. *Douglas S.J., Bird F.R. Drug adsorbates. U.S. Pat. No. 5,032,393 to Glaxo group Ltd.; 1991.*
54. *Metcalf, S., Purdy, K. Pharmaceutical formulation comprising a 2-aminoacetamide derivative and an ion exchange resins. U.S. Pat. No. 6,193,962 to Astrazeneca U.K. Ltd; 2001.*
55. *Borodkin, S., Yunker, M.H. Interaction of amine drugs with a polycarboxylic acid ion exchange resins. J. Pharm. Sci. 1970; 59: 481-486.*
56. *Swarbrick, J., Boylan, S.c. (eds). Chewable Tablets in Encyclopedia of Pharmaceutical Technology (Vol. 2). New York: Marcel Dekker Inc. ; 1990. p.400-402*
57. *Roy, G.M. Taste masking in oral pharmaceuticals. Pharm. Tech. 1994; 18: 84-99.*
58. *Fulzele, S.V.,Jaiswal, S.B.. Preliminery studies on the development of new non- bitter chloroquine formation using tannic acid. Indian J. Pharm. Sci. 2001; 63: 45-48.*
59. *Tsau, J.H., Damani, N.C. Taste masking compositions. U.S. Pat. No. 4,971, 791 to The Procter and Gamble Company; 1990.*
60. *Appelgren, C., Eskilson, C. A novel method for the granulation and coating of pharmacologically active substances. Drug Dev. Ind. Pharm. 1990; 16: 2345-2351.*
61. *Mackles, L., Chavkin, L., Tasteless forms of basic drugs prepared by absorption in situ. U.S. Pat. No. 5, 811, 131 to Behr Esg.; 1998.*
62. *Hussain, M.A., August, B.J. Improved buccal delivery of opioid analgesics and antiagonists with bitterless prodrugs. Pharm. Res. 1988; 5: 615- 618.*
63. *Taylor, E.P.. A tasteless derivative of chloramphenicol. J. Pharm. Pharmacol. 1953; 5: 254-256.*
64. *Sinkula, A.A., Yalkowsky, S.H. Rationale for design of biologically reversible drug derivatives. J.Pharm. Sci. 1975; 64: 200-203.*

SJIF Impact Factor (2026): 8.863| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 11 | Issue: 5 | May 2026 - Peer Reviewed Journal

65. *Brahamnkar, D.M., Jaiswal, S.B. Prodrugs. In Biopharmaceutics and Pharmacokinetics; A Treatise. Vallabh Prakashan. Delhi; 1998. p163.*
66. *Russel, S.J., Paul, A.S. Suppression of bitterness using sodium salts. Flavours and Fragrances. 2001; 55: 441-447.*
67. *Breshlin, P.A.S., beauchamp, G.K. Suppression of bitterness by sodium variation among bitter taste stimuli. Chemical Senses. 1995; 20: 609-623.*
68. *Katsuragi, Y., Sugiura, Y. Selective nhibition of bitter taste of various drugs by lipoprotein. Pharm. Res. 1995; 12: 658-662.*
69. *Katsurgi, Y., Yasumasu, T. Lipoprotein that selectively inhibits taste nerve responses to bitter substances. Brain Res. 1996; 713: 240-245.*
70. *Katsurgi, Y., Kashiwayanagi, M. Specific inhibitor for bitter taste inhibition of taste nerve responses and human taste sensation to bitter stimuli. Brain Res Protocols.1997; 1: 292-298.*
71. *Katsurgi, Y., Mitsui, Y. Basic studies for the practical use of bitterness inhibitors. Pharm. Res. 1997; 14: 720-724.*
72. *Saito, M., Masahiro, H. The marked inhibitions of the bitter taste of Polymixin B sulfate and Trimethoprim- Sulfamethoxazole by flavored BMI 60 in padiatric patients. Biol. Pharm. Bull. 1999; 22: 997-998.*
73. *Rao, M.Y.., Bader, F. Masking the taste of chloroquine by preparing multiple emulsions. The Eastern Pharmacists. 1991; November: 123-124*
74. *Vazliri, A., warburton, B. Slow release of chloroquine phosphate from multiple taste masked w/o/w multiple emulsion. J. Microencap. 1994; 11: 641-648*
75. *Kaning, K., Kanada, K. Application of gel formation for taste masking. Chem. Pharm. Bull. 1997; 45: 1063-1068.*
76. *Niazi,S., Shamesh, A. Chewing gum containing a medicament and taste maskers. US Patent 04,639,368; January 27, 1987.*
77. *Pather, S.I., Khankari, R.K., Eichman, J.D., Robinson, J.R., Hontz, J. Sublingual buccal effervescent. US Patent 20,020,110,578:August 15, 2002.*
78. *Blasé, C.M., Shah, M.N. Taste masked pharmaceutical suspensions for pharmaceutical actives. Eur. Pat. Appl. EP0556057; August 18, 1993.*
79. *Skraanga, A.T.P., Tully, R.E. Oral liquid antidepressant ssolution. U.S. Patent 6,040,301; March 31,2000.*
80. *Swarbrik, J., Boylan, S.C. (Eds.) Flavors and flavors modifier. In Encyclopedia of Pharmaceutical Technology(Vol. 6). New York: Marcel Dekker Inc.; 1990. p 117-137.*
81. *Takagi, S., Toka, K. Detection of suppression of bitterness by sweet substance using a multichannel taste sensor. J. Pharm. Sci. 1998; 87: 552-555.*
82. *Uchida, T., Miyanaga, Y. Quantitative evaluation of the bitterness of commercial medicines using a taste sensor. Chem. Pharm. Bull. 2000; 48: 1843-1845.*
83. *Shirai Y., Sogo K. A novel fine granules system for masking bitter taste. Biol. Pharm. Bull. 1993; 16: 172-177.*
84. *Amol G. Jadhao, Prachi S. Mankar, Pooja B. Kharat, Vaishnavi N. Thakare, Vaishnavi Navtahle, Punam S. Narwade. Dr. Jayshri B. Sanap. Komal N. Mohite, Manisha R. Jawale. Prashant A. Patil, Department of Pharmaceutics, Gawande College of Pharmacy, Sakharkherda, Maharashtra, India, Formulation and Various Pharmacological Properties of Hibiscus Rosa Sinesis, International Journal of Trend in Scientific Research and Development.*
85. *Amol G. Jadhao, Chaitanya D. Ghode, Nikhil S. Gulbane, Pallavi S. Morande, Prashant A. Patil, Sheikh Sakib Sheikh Shakiq, Mayuri M. Kale "Uses & Soxhlet Extraction of Apigenin from Parsley (Petroselinum Crispum)" Published in International Journal of Trend in Scientific Research and Development.*
86. *86.Amol G Jadhao. Kiran Wadatkar, Sakshi Waghmare, Prashant A Patil Gawande College of Pharmacy. Sakharkherda. Maharashtra, India, Various Formulation and Pharmacological Properties of Chinese Chaste Tree, International Journal of Trend in Scientific Research and Development.*
87. *Amol G. Jadhaol Ganesh J. Pimplel. Priyanka G. Talel, Sandhya S. Sonsalel. Prachi B. Rauti, Prashant A. Patil3, Vaishali B. Magar4 1Gawande College of Pharmacy, Sakharkherda. Buldana, Maharashtra. India, Formulation, Evaluation and Various Pharmacological Properties and Uses of Thyme*
88. *Jadhao AG, Devkar M J, Shaikh S S, M., Sau, Evaluation of Herbal Syrup, Asian Journal of Pharmaceutical Research and Development, Gawande College of Pharmacy, Sakharkherda. Is. Sindkhed Raja, Buldana. Mabarastra. India*
89. *Mr Amol G. Jadhao, 2Miss. Sakshi S. Ingle, 3Mr. Umesh D. Solake, 4Miss. Mayuri G. Zore, SMiss. Jayshri B. Sanap, 1Assitant Professor & HOD, 2,3 Students of B. Pharm Final Year, 4Lecturer, 5Associate Professor & Principal Pharmaceutics Department Gawande College of Pharmacy Sakbarkherda. Buldana, Maharashtra, India, Teratogenic Effect of Different Drugs at Different Stages of Pregnancy.*
90. *Amol G. Jadhao, Vrushali S. Borey, Saurabh. B. Ingle, Pooja V. Kotwal, Taufik R. Sheikh. Shtrughan, U. Nagrik, Jayshri B. Sanap, Gawande College of Pharmacy, Sakharkherda. Dist Buldana (Maharastra). India, Recent Advanced of Fabrication Techniques and Application of Micro-Needle*
91. *Mr. Amol G. Jadhao 2Mahewish W. Shaikh, Mr. Taufik R. Shaikh, Miss. Jayshri B. Sauap, Student of B. Pharm final year, Gawande College of Pharmacy, Sakharkherda.. Assitant Professor Gawande College of pharmacy. Sakharkherda (Department of Pharmaceutics), At. Post: Kalambeshwar. To. Mehkar, Dist. Buldana-443304, Fabrication and Evaluation of Drug Loaded Solid Liquid Nanoparticles for Oral Delivery.*